Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-ranging study of AZD3427 in pulmonary hypertension due to left heart disease associated with heart failure
CTR20234266Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AZD3427 in pulmonary hypertension due to left heart disease (PH-LHD), heart failure (HF), sponsored by AstraZeneca. Started Dec 2023; status: completed.
02
Drugs
AZD3427
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)heart failure (HF)
Beyond the preview
Go deeper on CTR20234266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234266.